Molecular modeling studies, synthesis, configurational stability and biological activity of 8-chloro-2,3,5,6-tetrahydro-3,6-dimethyl-pyrrolo[1,2,3-de]-1,2,4-benzothiadiazine 1,1-dioxide by Battisti, UMBERTO MARIA et al.
Bioorganic & Medicinal Chemistry 19 (2011) 7111–7119Contents lists available at SciVerse ScienceDirect
Bioorganic & Medicinal Chemistry
journal homepage: www.elsevier .com/locate /bmcMolecular modeling studies, synthesis, conﬁgurational stability
and biological activity of 8-chloro-2,3,5,6-tetrahydro-3,6-dimethyl-pyrrolo
[1,2,3-de]-1,2,4-benzothiadiazine 1,1-dioxide
Umberto M. Battisti a, Marina M. Carrozzo b, Giuseppe Cannazza a,⇑, Giulia Puia c, Luigino Troisi b,
Daniela Braghiroli a, Carlo Parenti a, Krzysztof Jozwiak d
aDipartimento di Scienze Farmaceutiche, Università degli Studi di Modena e Reggio Emilia, Via Campi 183, 4100 Modena, Italy
bDipartimento di Scienze e Tecnologie Biologiche ed Ambientali, Università del Salento, Via Prov.le Lecce-Monteroni, 73100 Lecce, Italy
cDipartimento di Scienze Biomediche, Università degli Studi di Modena e Reggio Emilia, Via Campi 183, 41100 Modena, Italy
d Laboratory of Medicinal Chemistry and Neuroengineering, Department of Chemistry, Medical University of Lublin, ul.W.Chodzki 4a, 20-093 Lublin, Poland
a r t i c l e i n f oArticle history:
Received 28 June 2011
Revised 28 September 2011
Accepted 30 September 2011
Available online 5 October 2011
Keywords:
Benzothiadiazines
AMPA receptor
Positive modulators0968-0896/$ - see front matter  2011 Elsevier Ltd. A
doi:10.1016/j.bmc.2011.09.063
⇑ Corresponding author. Tel.: +39 059 2055136; fax
E-mail address: giuseppe.cannazza@unimore.it (G.a b s t r a c t
The potential therapeutic beneﬁt of compounds able to activate AMPA receptors (AMPArs) has led to a
search for new AMPAr positive modulators. Among them, 8-chloro-2,3,5,6-tetrahydro-3,6-dimethyl-pyr-
rolo[1,2,3-de]-1,2,4-benzothiadiazine 1,1-dioxide (1) has attracted particular attention, because it is one
of the most active benzothiadiazine–derived positive modulators of the AMPA receptor. It possesses two
stereogenic centers, C3 and C6, thus it can exist as four stereoisomers. In this work, preliminary in silico
studies suggested that 1 interacts stereoselectively with AMPArs. Single stereoisomers of 1 were pre-
pared in order to evaluate their biological activity. However, studies regarding the conﬁgurational stabil-
ity of the investigated compounds suggested a rapid epimerization at C3 in aqueous solvents, and we can
expect the same reaction in vivo. Thus, electrophysiological experiments were performed on the two epi-
meric mixtures, (3⁄,6R)- and (3⁄,6S)- 8-chloro-2,3,5,6-tetrahydro-3,6-dimethyl-pyrrolo[1,2,3-de]-1,2,4-
benzothiadiazine 1,1-dioxide, in order to evaluate their activities as positive allosteric modulators of
AMPArs. The obtained data suggest that the (3⁄,6S) epimeric mixture is the most active in positively mod-
ulating AMPArs, conﬁrming in silico results.
 2011 Elsevier Ltd. All rights reserved.1. Introduction
L-Glutamate is the principal excitatory neurotransmitter in the
mammalian central nervous system (CNS), which can activate
ionotropic and metabotropic receptors.1–4 An excessive excitation
of glutamate receptors observed during stroke, ischemia and sim-
ilar conditions, mainly due to uncontrolled release of glutamate,
leads to neuronal degeneration. On the other hand, reduced func-
tionality of such receptors seems to be involved in learning and
memory deﬁcits associated with neurodegenerative diseases like
Alzheimer’s disease and schizophrenia.5 Many studies have been
carried out to develop compounds able to enhance glutamatergic
function without causing excitotoxicity. In this context, there is a
rapidly growing interest in positive allosteric modulators of the
a-amino-3-hydroxy-5-methyl-4-isoxazolpropionic acid receptor
(AMPAr) for their therapeutic properties as potentiators of gluta-
matergic function without the side effects of direct agonists.1–5ll rights reserved.
: +39 059 2055750.
Cannazza).Several positive modulators of AMPA receptors have been de-
scribed in the last two decades.6–14 These agents bind to allosteric
sites and enhance receptor function by decreasing desensitization
and/or deactivation.
Among the different classes of positive allosteric modulators of
AMPArs, benzothiadiazines are one of the most investigated, sug-
gesting their potential utility for a variety of clinical indications
such as schizophrenia, depression, Alzheimer’s disease, Parkinson’s
disease, ADHD, and respiratory depression.13–21
Compound 1 (Fig. 1) has attracted particular attention, since it
is one of the most active benzothiadiazine-derived positive modu-
lators of the AMPA receptor.15 Compound 1 possesses two stereo-
genic centers, C3 and C6, thus it can exist as four stereoisomers
(Fig. 1). A primary goal of the present work was to evaluate stere-
oselective interaction of 1 with the AMPAr GluA2 subunit using
docking studies.
In order to conﬁrm the results obtained by docking studies, sin-
gle stereoisomers of 1 were synthesized and their biological activ-
ity was evaluated.
Since it is known that chiral 2,3-dihydrobenzothiadiazines
are conﬁgurationally labile, it became important to evaluate the
Figure 2. MVD docking template (IDRA21). Yellow: ring atoms; green: hydrogen-
bond acceptors; purple: hydrogen-bond donors, gray: steric.
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Figure 1. Stereoisomers of 8-chloro-2,3,5,6-tetrahydro-3,6-dimethyl-pyrrolo[1,2,3-
de]-1,2,4-benzothiadiazine 1,1-dioxide (1).
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macological results.22–28
With this aim, the stopped-ﬂow bidimensional recycling HPLC
(sf-BD-rHPLC) method, recently developed by our research group,
was employed to investigate stereo and chemical stability of1under
conditions similar to those of pharmacological experiments.26,27
2. Results and discussion
2.1. Docking studies
Since previous studies suggested that chiral benzothiadiazines
display a stereoselective pharmacological action, it was important
to evaluate the activity of single stereoisomers of 1 as AMPAr
modulators.29,30
Taking advantage of crystal structures of the AMPA GluA2 ligand
binding domain co-crystallized with several benzothiadiazines,
Molegro Virtual Docker (MVD) software was applied to dock 1with
the binding pocket of the GluA2 dimer interface.31,32 The software
MVD was evaluated on cyclothiazide, IDRA21, trichloromethiazide
and hydrochlorothiazide. The average root mean square distance
(RMSD) of the best ranked pose of tested compounds compared
to their binding pose in their respective crystal structures was
found to be 0.66 Å (CTZ 0.41 Å; IDRA21 0.50 Å; trichlormethiazide
0.77 Å; hydrochlorothiazide 0.97 Å), proving that MVD is able to
accurately dock this class of compounds.31 Among the tested crystal
structures, the GluA2 dimer in complex with IDRA21 was selected
for docking studies of 1. Before docking 1, a conformational analysis
was necessary to identify possible bioactive conformations to use as
input structures. As reported by Harpsoe et al. the ﬂexibility of 1 re-
sides only in the sulfonamidic ring.29 Since two ring conformations
are possible and the hydrogen atom on N2 can be located in an axial
or equatorial position, there are four possible conformers for each
stereoisomer of 1. The global energy minimum conformer was pre-
viously calculated to have the N2 hydrogen in an axial position and
the methyl substituent at C3 in an equatorial position.29 IDRA21
displays an analogous conformation in the crystal structure in com-
plex with the GluA2 dimer (PDB code 3IL1) conﬁrming that the con-
former with an N2 axial hydrogen and a C3 equatorial methyl could
be employed for further docking studies.31 The docking protocol
template was built using the following chemical properties ofIDRA21: ring atoms, hydrogen-bond acceptors, hydrogen-bond
donors, and steric interactions (Fig. 2). The docking output clearly
indicated a common orientation of the benzothiadiazine core in
the ligand binding site for each stereoisomer of 1 (Fig. 3).
The principal interactions were between N4 and a sulfone oxy-
gen of the benzothiadiazine with S754 and G731 of the GluA2
domain, respectively.31 These interactions were observed for all
stereoisomers of 1 in the best ranked poses. Furthermore MVD
software predicted the highest afﬁnity stereoisomer to be
(3S,6S)-1 (Table 1).
The S conﬁguration of the C3 atom imposes an axial orientation
on the N2 hydrogen, allowing a polar interaction between the li-
gand and P494 (Fig. 4). An analogous interaction was observed in
the S1S2 GluA2 crystal structure in complex with IDRA21, suggest-
ing that this interaction is probably responsible for the higher
afﬁnity of the 3S diastereomers of 1 compared to their 3R analogs.
The distance between the N2 hydrogen of (3S,6S)-1 and the car-
bonyl oxygen of P494 is 2.81 Å (Fig. 4); when the conﬁguration
of C3 is reversed in (3R,6S)-1 the bond distance increases to
5.23 Å (Fig. 4). Moreover the S conﬁguration of the C6 atom permits
the methyl group on C3 to point directly to the lipophilic cleft
formed by the backbone of P494, F495 and M496 (Fig. 3C).29
Furthermore (3S,6R)-1 shows a lower afﬁnity value respect to
(3S,6S)-1, probably due to the steric hindrance between a C6
methyl group in an R conﬁguration and S729 (Fig. 5).29,31 Docking
output poses indicate a dramatic decrease in afﬁnity for (3R,6S)-1
compared to (3S,6S)-1, due to the lack of a polar interaction
between the N2 hydrogen and P494 (Fig. 3B). (3R,6R)-1 is the least
active stereoisomer due to steric interaction between the C6
methyl group and S729 and the absence of polar interaction be-
tween the N2 hydrogen and P494 (Fig. 3D).
2.2. Synthetic procedures
The mixture of all four stereoisomers of 1 was synthesized as
previously reported by Philips et al.15 In a ﬁrst effort to obtain single
stereoisomers of 1, the mixture was tentatively separated on differ-
ent commercially available chiral stationary phases (CSPs) (OJ, OB,
OD). Unfortunately, no baseline resolution was observed for any
of the chromatographic conditions tested. Hence, the two epimeric
mixtures of 1were obtained following a synthetic/chromatographic
strategy similar to that previously developed for a compound struc-
turally related to 1 (Scheme 1).26 Brieﬂy, single enantiomers of 2,3-
dihydro-3-methyl-1H-indole (3) were obtained by derivatization of
racemic 3with di-tert-butyl dicarbonate (BOC2O) to afford 4. Enan-
tioresolution of 4 by chiral chromatography on a semipreparative
Figure 3. Binding mode of (3S,6S)-1 (A), (3R,6S)-1 (B), (3S,6R)-1 (C), (3R,6R)-1 (D) and IDRA21(gray) in S1S2J GluA2.
Table 1
Docking results for the four stereoisomers of 1
Stereoisomer of 1 Moldock Rerank
3S,6S 106.8 86.9
3R,6S 101.1 81.5
3R,6R 96.7 74.0
3S,6R 104.3 84.2
(3S,6S)-1 Isomer possesses the lowest scoring, while the (3R,6R)-1 isomer possesses
the highest scoring (lowest binding). These data suggest that the S conﬁguration is
preferred over the R at both chiral centers.
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enantiomers were then deprotected, and absolute conﬁgurations
of single enantiomers of 3 were assigned by comparing optical
rotation data with those reported in literature.26,33 (S)- and (R)-Figure 4. Binding mode of (3R,2,3-dihydro-3-methyl-1H-indole (S-3 and R-3) enantiomers were
employed to prepare (S)- and (R)-2,3-dihydro-3-methyl-1H-indol-
7-sulfonamide (S-5 and R-5). Subsequently the epimeric mixtures
(3⁄,6R)-6 and (3⁄,6S)-6 were obtained by ring closure of (R)-2,3-
dihydro-3-methyl-1H-indol-7-sulfonamide (R-5) and (S)-2,3-dihy-
dro-3-methyl-1H-indol-7-sulfonamide (S-5) with acetaldehyde.
(3⁄,6R)-6 and (3⁄,6S)-6 were chlorinated with N-chlorosuccinimide
in order to obtain the epimericmixtures (3⁄,6R)-1 and (3⁄,6S)-1 (See
Section 4).
The two epimeric mixtures of 1 were subsequently resolved by
chromatography employing a Chiralcel OD column under both
normal and reverse phase conditions. A baseline separation was
obtained for (3⁄,6R)-1 epimers while a partial separation was
achieved for (3⁄,6S)-1 epimers.
In order to isolate the single epimers of (3⁄,6R)-1, the analytical
method was scaled to a semipreparative level. By employing a6S)-1 (a) and (3S,6S)-1 (b).
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Scheme 1. Synthetic/chromatographic preparation of epimeric mixtures of 1.
Figure 5. Docking of (3S,6R)-1 (a) and (3S,6S)-1 (b) at the GluA2 dimer interface (hydrophobic residues are in blue, hydrophilic residues are in red).
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70:30 (v/v) as a mobile phase, fractions corresponding to single
epimers of 1 were harvested.
The epimeric composition of each fraction was determined
prior to and after evaporation of mobile phase (70:30 v/v hex-
ane/2-propano) under reduced pressure. Single pure stereoiso-
mers were present prior to evaporation of mobile phase, while
the epimeric mixture was detected after evaporation of solvents.
These results indicate that single stereoisomers of 1 undergo a
rapid epimerization process during evaporation of mobile phase,
suggesting that the chiral C3 atom of 1 is conﬁgurationally
unstable.
Hence, before performing studies of biological activity on single
stereoisomers of 1, it was important to evaluate their conﬁgura-
tional stability in order to obtain reliable pharmacological results.2.3. Conﬁgurational and chemical stability of 8-chloro-2,3,5,6-
tetrahydro-3,6-dimethyl-pyrrolo[1,2,3-de]-1,2,4-
benzothiadiazine, 1,1-dioxide (1)
Preliminary investigations concerning conﬁgurational stability
of epimeric mixture (3⁄,6R)-1were performed by dynamic chroma-
tography (DHPLC). When (3⁄,6R)-1 was chromatographed on a
Chiralcel OD column at temperatures above 25 C employing
water/acetonitrile as a mobile phase, an epimeric plateau was ob-
served between the two peaks. No epimerization occurred during
separation on a Chiralcel OD column using non aqueous solvents
as mobile phase (hexane/2-propanol). These data are in accordance
with our previous studies that indicated a rapid enantiomerization
in aqueous solvents at chiral carbon C3 of 2,3-dihydrobenzothiadi-
azine type compounds structurally related to 122–28 (Scheme 2).
Cl
N
NH
S
H3C
CH3
O O
*
S
a)
b)
Cl
NH
N
S
H3C
CH3
O O
*
Cl
N
NH2
S
H3C
CH3
O O
*
+
Cl
N
NH
S
H3C
CH3
O O
*
R
Scheme 2. Proposed epimerization mechanism. (a) Neutral/basic conditions (b) acidic conditions.
U. M. Battisti et al. / Bioorg. Med. Chem. 19 (2011) 7111–7119 7115Employing DCXplorer software developed by Trapp, it was pos-
sible to calculate epimerization rate constants by integration of the
area of the interconverting peaks.34–43
The analysis of (3⁄,6R)-1 was performed at different tempera-
tures between 5 and 37 C using a Chiralcel OD-R column and
50:50 (v/v) water/acetonitrile as mobile phase. The rate constants
and free energy barriers of epimerization calculated with DCXplor-
er are reported in Table 2. The data obtained indicated that the epi-
merization rate increases with increases in temperature. Dynamic
chromatographic methods, however, constrained calculation of
epimerization kinetic constants of (3⁄,6R)-1 in the presence of chi-
ral stationary phase (CSP) and mobile phase, which could inﬂuence
reaction rates. Therefore kinetic parameters of epimerization ob-
tained by dynamic chromatography can be different from those ob-
tained when stereoisomers are dissolved in biological ﬂuids and
are in contact with cellular membranes.
Recently we developed a stopped-ﬂow bidimensional recycling
HPLC (sf-BD-rHPLC) method that permits the evaluation of conﬁg-
urational and chemical stability of pharmaceutical compounds
under conditions similar to those in vivo.26,27 The method offers
several advantages with respect to methods reported in literature.
In particular it allows the calculation of epimerization rate con-
stants on the epimeric mixture directly without the necessity of
having single epimers like the classical batch-wise method. It is
possible to conduct epimerization in solvents similar to physio-
logical ﬂuids and not in mobile phase that contains an organic
modiﬁer that could inﬂuence rate of interconversion like in dy-
namic and stopped-ﬂow methods. Moreover, the sf-BD-rHPLC
method permits one to choose the appropriate stationary phase
in which epimerization will be conducted; in this manner it is
possible to avoid stereospeciﬁc interactions that could stabilize
one stereoisomer over another thus inﬂuencing epimerization
rates.
Since epimers are contact with biological membranes and dis-
solved in physiological solutions in biological activity experiments,
conﬁgurational stability canbeevaluatedunder the sameconditionsTable 2
Epimerization of (3⁄,6R)-1 at different temperatures by DCXplorer
Temperature (C) kA-to-B (s1) kB-to-A (s1)
5 0.17 ± 0.10  104 0.06 ± 0.06 
25 1.11 ± 0.02  104 0.76 ± 0.01 
37 1.28 ± 0.29  104 0.71 ± 0.11 
Column: Chiralcel OD-R; Temperatures: 5, 25 and 37 C. Eluents: water/acetonitrile 50:in order to obtain reliable biological activity data for single stereo-
isomers of 1.
Recently stationary phases that simulate biological membranes
were employed in the evaluation of solute/membrane partition
coefﬁcients of pharmaceutical compounds.44–46 In particular C8
and C18 stationary phases were extensively employed to evaluate
partition coefﬁcients giving good correlation with logP obtained
with the classical octanol/water distribution method. More re-
cently, an immobilized artiﬁcial membrane (IAM) stationary phase
composed of lecithin monolayers (phosphatidylcholine), wherein
each lipid molecule is covalently linked to propylamine/silica, be-
came commercially available, enabling the accurate calculation of
solute/membrane partition coefﬁcients.46–49
Hence, by using C8 or IAM stationary phases as reactor columns
in the sf-BD-rHPLC method it was possible to evaluate the conﬁg-
urational stability of (3⁄,6R)-1 under experimental conditions that
resemble those of the stomach (pH 2.2) and plasma (pH 7.0) at
37.5 C.
The data obtained with the sf-BD-rHPLC method, reported in
Tables 3 and 4, indicated that epimerization occurs with similar
kinetics on both C8 and IAM columns with half-times in the range
of 10–20 min. Moreover, pH slightly inﬂuenced the rate constants
of epimerization, since only small differences were observed at the
two pH’s tested. These data suggest that the in vivo administration
of single stereoisomers of 1 lacks signiﬁcance since it could under-
go epimerization before reaching the target receptor in the brain.
Surprisingly compound 1 was stable to hydrolysis under acidic
conditions, since no hydrolysis occurred at pH 2.2 at 37.5 C for at
least 90 min.
Previous studies on the chemical stability of benzothiadiazines
structurally related to 1, like IDRA21, indicated their rapid hydroly-
sis in acidic solvents.22–28 Further studies have suggested that
IDRA21, when orally administered, hydrolyzes in 2-amino-5-chlo-
robenzensulfonamide,whichwas detected at high levels in rat brain
together with single enantiomers of IDRA21 itself.50 The data ob-
tained with the sf-BD-rHPLC method indicate that 1 is more stablekA-to-eq (s1) DG#Atoeq (kJ/mol)
104 0.23 ± 0.16  104 91.06 ± 1.22
104 1.87 ± 0.02  104 93.86 ± 0.03
104 1.99 ± 0.41  104 96.41 ± 0.47
50 (v/v). Flow rate: 0.5 mL/min.
Table 4
Epimerization of (3⁄,6R)-1 by sf-BD-rHPLC on an IAM stationary phase column
pH kA-to-eq (s1) kB-to-eq (s1) kA-to-B (s1) kB-to-A (s1) DG#Atoeq (kJ/mol) DG
#
Btoeq (kJ/mol)
2.2 10.70 ± 0.03  104a 9.63 ± 0.07  104a 6.68 ± 0.35  104 3.48 ± 0.18  104 92.07 ± 0.08b 92.34 ± 0.02b
7.0 7.20 ± 0.55  104a 8.93 ± 0.48  104a 5.30 ± 0.57  104 2.75 ± 0.29  104 93.09 ± 0.19b 92.53 ± 0.14b
Separative column: Chiralcel OD-R. Reactor column: IAM based. Column operation temperature at 0 C n = 4. Eluent (pump 1): water/acetonitrile 50:50 (v/v). Buffers (pump
2): chloroacetate buffer solution of ionic strength of 0.01 at pH 2.20 and phosphate buffer solution of ionic strength of 0.01 at pH 7.00. Time intervals for enantiomerization at
37.5 C = 50 , 100 , 150 , 200 , 300 .
a Rate constants on an IAM column.
b Free energy barriers on an IAM column.
Table 3
Epimerization of (3⁄,6R)-1 by sf-BD-rHPLC on a C8 column
pH kA-to-eq (s1) kB-to-eq (s1) kA-to-B (s1) kB-to-A (s1) DG#Atoeq (kJ/mol) DG
#
Btoeq (kJ/mol)
2.2 6.68 ± 0.48  104a 6.52 ± 0.79  104a 4.61 ± 0.22  104 2.26 ± 0.03  104 93.28 ± 0.18b 93.35 ± 0.30b
7.0 5.90 ± 0.56  104a 7.77 ± 0.32  104a 4.49 ± 0.61  104 2.34 ± 0.32  104 93.60 ± 0.23b 92.89 ± 0.10b
Separative column: Chiralcel OD-R. Reactor column: Supelcosil LC-8. Column operation temperature at 0 C n = 4. Eluent (pump 1): water/acetonitrile 50:50 (v/v). Buffers
(pump 2): Chloroacetate buffer solution of ionic strength of 0.01 at pH 2.20 and phosphate buffer solution of ionic strength of 0.01 at pH 7.00. Time intervals for
enantiomerization at 37.5 C = 50 , 100 , 150 , 200 , 300.
a Rate constants on a C8 column.
b Free energy barriers on a C8 column.
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be hypothesized that 1 would not undergo hydrolysis to the corre-
sponding benzensulfonamide when orally administered.
In vivo pharmacokinetic experiments in rats are in development
in order to conﬁrm the chemical stability of 1 towards acidic
conditions like those of stomach.
2.4. Biological activity
Data obtained by the sf-BD-rHPLC method clearly indicated that
single stereoisomers of 1 in saline solution undergo fast epimeriza-
tion. Hence, testing single stereoisomers of 1 lacks signiﬁcance,
since biological tests are performed in saline solution. Therefore,
biological activity was evaluated on epimeric mixtures (3⁄,6R)-1
and (3⁄,6S)-1.
By using the patch clamp technique in whole cell conﬁguration,
Kainate (KA)-evoked currents were recorded from cortical neurons
grown in primary cultures. KA evoked currents, mediated mainly
by AMPAr, were potentiated by the co-application of epimeric mix-
tures (3⁄,6R)-1 or (3⁄,6S)-1.
(3⁄,6R)-1 and (3⁄,6S)-1, at a concentration of 100 lM, increased
KA currents by 112.3 ± 17.2% (mean ± SE) (n = 4) and 249.7 ± 50.3%
(mean ± SE) (n = 4), respectively. The difference in biological activ-
ity between the two epimeric mixtures was statistically signiﬁcant
(t-test, p <0.05).
These data indicate that the epimeric mixture (3⁄,6S)-1 is much
more active in potentiating KA-evoked currents than the epimeric
mixture (3⁄,6R)-1. These experimental results are in accordance
with docking results that indicate that (3S,6S)-1 is the most active
of all four stereoisomers.
3. Conclusion
The stereoselectivity of compound 1 as an AMPAr positive allo-
steric modulator was investigated. Molecular docking simulations
were used to investigate possible binding poses of the four stereo-
isomers of 1. These simulations conﬁrmed that stereoisomers of 1
can display different interactions with the allosteric ligand binding
site of AMPAr and thus have different levels of activity. Subse-
quently, in order to obtain single stereoisomers of 1, a synthetic
and a chromatographic strategy was developed. Investigation ofthe stability of stereoisomers of 1 suggested that the C3 atom is
a labile chiral center in aqueous solvents. Moreover, biological
in vitro assays were conducted on both epimeric mixtures
(3⁄,6S)-1, (3⁄,6R)-1 and the results suggest that (3⁄,6S)-1 is signiﬁ-
cantly more active than (3⁄,6R)-1 as positive modulator of the
AMPA receptor. These biological data are in accordance with in
silico results.
4. Experimental
4.1. Instrumentation
The chromatographic apparatus was a Shimadzu LC-10AD
Pump (Shimadzu Italia, Milan), a Merck Hitachi L-6200A Pump
(Merck KGaA, Darmstadt, Germany), and a Rheodyne 7725 man-
ual injector equipped with a 20 lL sample loop (Jasco Europe,
Italy, Milan). A Merck Hitachi L-7400UV (Merck KGaA, Darmstadt,
Germany) was used as detector. Chromatograms were recorded
with a Jasco J-700 program (Jasco Europe, Italy, Milan). Two Rhe-
odyne 7000 valves were used to switch the mobile phase ﬂow
(Jasco Europe, Italy, Milan). Column temperature regulation was
obtained with a Jasco CO-2067 column oven (Jasco Europe, Italy,
Milan).
The columns used were a Chiralcel OD-R [cellulose tris
(3,5-dimethylphenylcarbamate); 250  4.6 mm I.D.; 10 lm], a Chi-
ralcel OD [cellulose tris (3,5-dimethylphenylcarbamate);
250  10 mm I.D.; 10 lm], a Chiralcel OJ-RH [cellulose tris (4-
methylbenzoate); 150  4.6 mm I.D.; 5 lm], and a Chiralcel OB-H
[cellulose tribenzoate; 250  4.6 mm I:D.; 5 lm] purchased from
Chiral Technologies Europe, Illkirch, France. Also used were a Supe-
lcosil LC-8 (250 mm  4.6 mm ID; 5 lm) purchased from Supelco
Italy, Milan, and a Lichrospher Si60 (250  10 mm I.D.; 10 lm), pur-
chased from Merck, German. Optical rotations (a) were measured
with a P-2000 Digital Polarimeter (cell-length 100 mm, volume
1 mL) from Jasco Europe, Italy, Milan.
Melting points were determined with an Electrothermal Appa-
ratus, and they are uncorrected.
IR spectra were recorded on a PerkinElmer Model 1600 FT-IR
spectrometer. 1H NMR spectra were recorded with a Brucker
DPX 200 spectrometer with DMSO-d6 as solvent and tetramethyl-
silane (TMS) as an external standard. Chemical shifts (d) are in
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ities are abbreviated as follows: s, singlet; d, doublet; dd, double
doublet; dt, double triplet; t, triplet; m, multiplet. The electro-
spray ionization (HR-ESI-MS) experiments were carried out on a
hybrid QqTOF mass spectrometer (PE SCIEX-QSTAR) equipped
with an ion spray ionization source. MS (+) spectra were acquired
by direct infusion (5 mL/min) of a solution containing the appro-
priate sample (10 pmol/mL), dissolved in a solution of 50:50
methanol/water containing 0.1% acetic acid at the optimum ion
voltage of 4800 V.
LC–MS experiments were carried out on an Agilent 1200 series
LC and interfaced to an Agilent 6410 triple-quadrupole mass spec-
trometer equipped with an electrospray ionization source. All data
were acquired and analyzed using Agilent MassHunter Quantita-
tive Analyses version B.01.04 analyst data processing software.
All pH measurements were made using an Orion Research
EA940 pH-meter.
HPLC-grade acetonitrile, n-hexane and 2-propanol were ob-
tained from Sigma–Aldrich (Milan, Italy).4.2. Docking studies
The GluA2-S1S2J crystal structure in complex with IDRA21 was
retrieved from the Protein Data Bank (PDB code: 3IL1) and im-
ported into MVD. All water molecules and co-factors were deleted.
All stereoisomers of compound 1 were built in Spartan and ener-
gies were minimized using theHartree–Fock ab initio method with
the 6-31G⁄ basis set.
The four isomers of 1 were then exported as mol2 ﬁles and
docked in GluA2 using MVD. We used the template docking avail-
able in MVD and evaluated MolDock score, Rerank score, and pro-
tein-ligand interaction score from MolDock and MolDock [GRID]
options. IDRA21 was selected as a reference compound for the
template. Default settings included a grid resolution of 0.30 Å,
the MolDock optimizer as a search algorithm, the number of runs
set to 10, a population size of 50, a maximum iteration of 2000, a
scaling factor of 0.50, and a crossover rate of 0.90. The maximum
number of poses generated was increased to 10 from a default va-
lue of 5.4.3. Synthesis
4.3.1. (3R,6R),(3S,6S),(3R,6S),(3S,6R)-8-Chloro-2,3,5,6-tetrahydro
-3,6-dimethyl-pyrrolo[1,2,3-de]-1,2,4-benzothiadiazine,1,1-
dioxide (1)
Compound 1 was synthesized as previously described by Philips
et al.15
Yield 27% (three steps), mp 185–187 C, 1H NMR (200 MHz,
CDCl3) d = 1.36 (d, J = 6.8 Hz, 3H), 1.52 (d, J = 6.1 Hz, 3H), 2.80
(dd, J = 11.3, 8.3 Hz, 1H), 3.40–3.47 (m, 1H), 3.74 (t, J = 8.3 Hz,
1H), 4.56 (d, J = 12.6 Hz, 1H), 4.68 (dq, J = 12.5, 6.1 Hz, 1H), 7.10–
7.22 (m, 1H), 7.30–7.47 (m, 1H).
HRMS-ESI: calcd for C11H14ClN2O2S [M+H]+ 273.0459; found:
273.0456.4.3.2. (3⁄,6R)-1 and (3⁄,6S)-1
4.3.2.1. 2,3-Dihydro-3-methyl-1H-indole (3). The compound
was synthesized as previously described by Gotor-Fernandez et al.
starting from 3-methylindole (2).33
Yield 90%, 1H NMR (200 MHz, CDCl3) d = 1.35 (d, J = 6.7 Hz, 3H),
3.13 (t, J = 8.5 Hz, 1H), 3.20 (s, broad, 1H), 3.38 (m, 1H), 3.72 (t,
J = 8.5 Hz, 1H), 6.68 (d, J = 7.7 Hz, 1H), 6.77 (dt, J = 7.4 Hz, 1.0 Hz,
1H); 7.03 (dt, J = 7.7 Hz, 1 Hz, 1H), 7.10 (d, J = 7.4 Hz, 1H).
HRMS-ESI: calcd for C9H12N [M+H]+ 134.1977; found: 134.1979.4.3.2.2. 2,3-Dihydro-3-methyl-1H-indole-1-carboxylic acid 1,1-
dimethyl ethyl ester (4). Compound 4 was synthesized as
previously described by Carrozzo et al.26
Yield 80%, 1H NMR (200 MHz, CDCl3) d = 1.33 (d, J = 6.7 Hz, 3H),
1.50-1.62 (s, broad, 9H), 3.37 (m, 1H), 3.50 (s, broad, 1H), 4.14 (t,
broad, J = 10.1 Hz, 1H), 6.68 (d, J = 7.7 Hz, 1H), 6.96 (dt, J = 7.4 Hz,
0.9 Hz, 1H); 7.13 (d, J = 7.4 Hz, 1H), 7.46-7.83 (s, broad, 1H).
HRMS-ESI: calcd for C14H20NO2 [M+H]+ 234.3135; found:
234.3137.
4.3.2.3. Semipreparative enantioseparation of 2,3-dihydro-3-
methyl-1H-indole-1-carboxylic acid 1,1-dimethyl ethyl ester
(4). Pure (+)(S) and (-)(R) enantiomers of 2,3-dihydro-3-
methyl-1H-indole-1-carboxylic acid 1,1-dimethyl ethyl ester were
obtained by semipreparative HPLC on a Chiralcel OD semiprepara-
tive column with fraction collection of the respective peaks. The
mobile phase consisted of n-hexane and 2-propanol 98:2 (v/v).
The compound was dissolved in n-hexane at a ﬁnal concentration
of 400 mg/mL. The injection volume was 500 lL. The detector was
set at 254 nm. The collected fractions corresponding to the enanti-
omers were analyzed by injection on the same column and under
the same chromatographic conditions.
4.3.2.4. (R)-2,3-Dihydro-3-methyl-1H-indol-7-sulfonamide ((R)-
5) and (S)-2,3-dihydro-3-methyl-1H-indol-7-sulfonamide ((S)-
5). The compounds were synthesized following the procedure
described by Philips et al.15
Yield 42%, mp 123–125 C, 1H NMR (200 MHz, CDCl3) d = 1.34
(d, J = 6.7 Hz, 3H), 3.25 (t, J = 8.2 Hz, 1H), 3.42 (m, 1H), 3.84 (t,
J = 8.7 Hz, 1H), 4.90 (s, broad, 2H), 5.26 (s, broad, 1H), 6.71 (t,
J = 7.3 Hz, 1H), 7.19 (dt, J = 7.1 Hz, 1.1 Hz, 1H), 7.44 (dt, J = 8.0 Hz,
0.9 Hz, 1H).
HRMS-ESI: calcd for C9H13N2O2S [M+H]+ 213.2762; found:
213.2761.
4.3.2.5. (3⁄,6R)-6 and (3⁄,6S)-6. The (3⁄,6R)-6 and (3⁄,6S)-6
were synthesized as previously described by Carrozzo et al.26
Yield 98%, mp = 170–173 C, 1H NMR (200 MHz, DMSO) d = 1.2
(d, J = 6.9 Hz, 1H), 1.30 (d, J = 6.7 Hz, 2H), 1.36–1.46 (m, 3H), 2.82
(dd, J = 11.1 Hz, 8.4 Hz, 0.67H), 3.22 (dd, J = 8.0 Hz, 2.5 Hz, 0.33
H), 3.30–3.40 (m, 1H), 3.48 (t, J = 8.7 Hz, 0.33 H), 3.72 (t,
J = 8.3 Hz, 0.67H), 4.56 (apparent sextet, J = 6.1 Hz, 0.67 H), 4.66
(apparent sextet, J = 6.1 Hz, 0.33 H), 6.71 (t, J = 7.2 Hz, 0.33 H),
6.77 (t, J = 7.2 Hz, 0.67 H), 7.18–7.30 (m, 2H), 7.82 (d, J = 11.4 Hz,
0.33 H), 7.89 (d, J = 11.4 Hz, 0.67H).
HRMS-ESI: calcd for C11H15N2O2S [M+H]+239.3134; found:
239.3136.
4.3.2.6. (3⁄,6R)-1 and (3⁄,6S)-1. To a solution of (3⁄,6R)-6 or
(3⁄,6S)-6 (1.0 mmol) in acetonitrile (20 mL) was added N-chloro-
succinimide (1.2 mmol). The reaction mixture was heated under
reﬂux conditions until no starting material was detected by TLC.
Subsequently water was added, and the resulting solution was ex-
tracted with ethyl acetate (EtOAc). The combined organic layer was
dried over anhydrous Na2SO4 and the solvent removed under vac-
uum. The solid residue was puriﬁed by column chromatography on
silica gel (elution solvent/ethyl acetate/petroleum ether (bp 40–
60 C), 1:1 (v/v).
Yield 94%, mp 185–187 C, 1H NMR (200 MHz, CDCl3) d = 1.36
(d, J = 6.8 Hz, 3H), 1.52 (d, J = 6.1 Hz, 3H), 2.80 (dd, J = 11.3,
8.3 Hz, 1H), 3.40–3.47 (m, 1H), 3.74 (t, J = 8.3 Hz, 1H), 4.56 (d,
J = 12.6 Hz, 1H), 4.68 (dq, J = 12.6, 6.1 Hz, 1H), 7.1–7.22 (m, 1H),
7.3–7.47 (m, 1H).
HRMS-ESI: calcd for C11H14ClN2O2S [M+H]+ 273.0459; found:
273.0456.
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4.4.1. (3⁄,6r)-1
Separation of (3⁄,6R)-1 was carried out isocratically at different
temperatures on a Chiralcel OD-R column. The mobile phase con-
sisted of water/acetonitrile 50:50 (v/v).
The compound was dissolved in acetonitrile and subsequently
diluted 1:10 (v/v) with mobile phase to a ﬁnal concentration of
100 lg/mL. The injection volume was 20 lL. The detector was set
at 254 nm.
4.4.2. (3⁄,6s)-1
Separation of (3⁄,6S)-1 was carried out isocratically on a Chiral-
cel OD-R column. The mobile phase consisted of water/acetonitrile
50:50 (v/v). The compound was dissolved in acetonitrile and sub-
sequently diluted 1:10 (v/v) with mobile phase to a ﬁnal concen-
tration of 100 lg/mL. The injection volume was 20 lL. The
detector was set at 254 nm.
4.4.3. (R,S)-5-chloro-2,3-dihydro-3-methyl-1H-indol-7-
sulfonamide (7)
Separation of (R,S)-5-chloro-2,3-dihydro-3-methyl-1H-indol-7-
sulfonamide from 1 was carried out isocratically on a Chiralcel
OD-R column. The mobile phase was water/acetonitrile 50:50 (v/
v).
The compound was dissolved in acetonitrile and subsequently
diluted 1:10 (v/v) with mobile phase to a ﬁnal concentration of
100 lg/mL. The injection volume was 20 lL. The detector was set
at 254 nm.
4.4.4. Chromatographic parameters
The separation factor (a) was calculated as k2/k1 and retention
factors (k1 and k2) as k1 = (t1t0)/t0 where t1 and t2 refer to the
retention times of the ﬁrst and second eluted enantiomers. The res-
olution factor (Rs) was calculated by the formula Rs = 2(t2t1)/
(w1+w2) where w1 and w2 are the peak widths at base for the ﬁrst
and second eluted enantiomers. The dead time of the columns (t0)
was determined by injection of 1,3,5-tri-tert-butylbenzene.4.4.5. Dynamic HPLC
Epimerization kinetic parameters of (3⁄,6R)-1were investigated
by dynamic chromatography experiments (DHPLC) using DCXplor-
er software developed by Trapp.34 The program employs the uni-
ﬁed equation of chromatography to directly evaluate elution
proﬁles in a graphical user interface.34–43 The software calculates
reaction rate constants by integration of the area of the intercon-
verting peaks.
Separation of (3⁄,6R)-1 epimers was carried out isocratically at
different temperatures (5–37 C) on a Chiralcel OD-R column using
water/acetonitrile 50:50 (v/v) as mobile phase.
Since chromatograms corresponding to separation of epimeric
mixture (3⁄,6R)-1 obtained by UV-detector showed an interfering
peak on the plateau region of interconverting epimers, DCXplorer
cannot be applied to evaluate kinetic parameters of epimerization
for (3⁄,6R)-1. Therefore, instead of a UV detector a mass spectrom-
eter was employed. This made it possible to extract chromato-
graphic traces corresponding to the molecular ion of compound 1
where the interfering peak was not present. An Agilent 1200 LC-
system was connected to a triple quadrupole mass spectrometer
(6410 Triple quadrupole) equipped with an electrospray ionization
source (ESI). Data were processed by acquisition/processing Agi-
lent MassHunter Quantitative software.
The mass spectrometer was operated in scan negative mode
between 200–300m/z, gas temperature 350 C, gas ﬂow (N2)
10 L/min, nebulizer 35 psi, capillary 3500 nA.Extracted ion chromatograms (MH 272m/z) row data in ASCII
were opened with the DCXplorer software and the elution proﬁles
were evaluated by zooming into the area of the interconverting
peaks. All chromatographic parameters were directly determined
by an integration method and were used to calculate reaction rate
constants.34–43
4.4.6. Stopped-ﬂow bidimensional recycling HPLC (sf-BD-
rHPLC)
The sf-BD-rHPLC method has been previously described.26,27
The epimeric mixture (3⁄,6R)-1 was injected on the ﬁrst column
(Chiralcel OD-R) and the individual epimers were quantitatively
separated at 0 C (step 1). At the appropriate time one of the two
epimers was trapped on the second column by switching valve 2
(step 2). Using pump 2 it was possible to ﬁll the second column
(Supelcosil LC-8 or IAM column) with a selected solvent at desired
pH and temperature (step 3). The epimerization was effected by
heating at 37.5 C while no mobile phase passed through column
2 (‘stopped-ﬂow’) for a set period of time. Afterwards the C8 col-
umn was cooled back to the previous low temperature (0 C) and
valve 1 was switched. The original mobile phase was reinforced
in column 2 by pump 2 to introduce the epimers onto the ﬁrst col-
umn (Chiralcel OD-R) where they were quantitatively separated
(step 4).
Three peaks appeared as expected: peak 1 corresponding to
untrapped epimer, peak 3 corresponding to epimer trapped in
step 2 while peak 2 arising from interconverted epimer formed
in step 3.
4.4.7. Calculation of kinetic rate constants and free energy
barriers of epimerization
The kinetic rate constants were calculated by ﬁtting the data to
Eqs. (1)–(3):
In
½A0  ½Aeq
½At  ½Aeq
¼ ðkAtoB þ KAtoBÞ ¼ kAtoeq  t ð1Þ
Keq ¼ kAtoBkBtoA ¼
½Beq
½Aeq
ð2Þ
kAtoeq ¼ kAtoBð1þ 1=KeqÞ ¼ kBtoAð1þ KeqÞ ð3Þ
where kA-to-B and kB-to-A are the rate constants of forward or back-
ward epimerization [s1], kA-to-eq is the rate constant of formation
of equilibrium mixture [s1], [A]0 concentration of decreasing ste-
reoisomer (A) at time 0, [A]t concentration of decreasing stereoiso-
mer (A) at time t, [A]eq concentration of decreasing stereoisomer (A)
at equilibrium, [B]eq concentration of increasing stereoisomer (B) at
equilibrium and t the epimerization time (s).
From the kinetic rate constants, the corresponding activation
energies of epimerization (rotational energy barriers) DG#(T) have
been calculated by the Eyring Eq. 4:
DG#ðTÞ ¼ RT ln kh
jkBT
 
ð4Þ
where k is kinetic rate constant, kB the Boltzmann constant
(kB = 1.380662  1023 J K1), h Planck’s constant (h = 6.626176
 1034 J s), R the universal gas constant (R = 8.31441 J K mol1), j
the transmission coefﬁcient (j = 0.5 for the reversible microscopic
interconversion) and T the temperature (K).4.5. Biological tests
4.5.1. Primary culture
Primary cultures of cortical neurons were prepared from new-
born Sprague–Dawley rats as reported in the literature.51 Brieﬂy,
cells from the cortex were dispersed with trypsin (0.24 mg/mL;
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cells/mL on 35 mm Falcon dishes coated with poly-L-lysine
(10 lg/mL, Sigma Aldrich). Cells were plated in basal Eagle’s Med-
ium (BME; Celbio, Milan, Italy), supplemented with 10% fetal bo-
vine serum (Celbio), 2 mM glutamine, 25 mM KCl and 100 lg/mL
gentamycin (Sigma Aldrich) and maintained at 37 C in 5% CO2.
After 24 h in vitro, the medium was replaced with 1:1 mixture of
BME and Neurobasal medium (Celbio, Milan) containing 2% B27
supplement, 1% antibiotic, and 0.25% glutamine (Invitrogen). At
5 days in vitro (DIV5), cytosine arabinofuranoside (Ara-C) was
added at a ﬁnal concentration of 1 lM.
4.5.2. Electrophysiological recordings
Recordings were performed at room temperature, under volt-
age-clamp in the whole-cell conﬁguration of the patch-clamp tech-
nique on cells at DIV7-10.52 Electrodes pulled from borosilicate
glass (Hidelberg, FRG) on a vertical puller (PB-7, Narishige) and
had a resistance of—MOhm. Currents were ampliﬁed with an Axo-
patch 1D ampliﬁer (Axon Instruments, Foster). The recording
chamber was continuously perfused at 5 mL/min with an artiﬁcial
extracellular solution composed of (mM): 145 NaCl, 5 KCl, 1 CaCl2,
5 Hepes, 5 Glucose, 20 Sucrose, pH 7.4 with NaOH. Electrode intra-
cellular solution contained (mM): 140 KCl, 3 MgCl2, 5 EGTA, 5
Hepes, 2 ATP-Na, pH 7.3 with KOH. Drugs were applied directly
by gravity through a Y-tube perfusion system.53
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